Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Pfizer

Unusual Options Activity Alert: 3 Stocks Setting Up for Major Profit Potential

Volatility returned to markets yesterday, triggering a tech rout. Among the unusually active options on Thursday were 278 calls and puts with Vol/OI ratios of 15 or higher. Among them, these 3 stocks offer options investors significant profit potential. Volatility returned to markets yesterday, triggering a tech rout. Among the…

Barchart

Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most

Pfizer stock jumped after a strong earnings beat and positive GLP-1 data, but investors may be overlooking a powerful oncology and AI-driven growth story.

MarketBeat

New weight loss drug by Pfizer shows promising results in trial

Pfizer acquired the drug’s developer following a bidding war with Novo Nordisk last year

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Nasdaq Futures Climb on Blowout Palantir Results

March Nasdaq 100 E-Mini futures (NQH26) are trending up +0.41% this morning as forecast-beating quarterly results and guidance from Palantir Technologies boosted sentiment.

Barchart

How Pfizer’s CEO wielded moral clarity to help his team do the impossible

The pharma company had to scale vaccine production from 200 million annually to 3 billion at the pandemic's peak.

Fortune

Pfizer CEO Albert Bourla's best leadership advice: Being optimistic is better than being right

Albert Bourla, the boss of the $150 billion pharmaceutical giant Pfizer, admits leaders don’t win by always being right—the key is being someone your peers want to follow.

Fortune

'We’ll save the world from cancer’: Inside Pfizer CEO’s $23 billion post‑COVID bet on oncology

"The winners in life are differentiated from the losers in life because the winners never fall," Albert Bourla says. "The winners always stand up again."

Fortune

Read news from The Economist, FT, and more,
with one subscription

Pfizer CEO says he used ‘emotional blackmail’ to get employees to achieve impossible goals during COVID-19

Albert Bourla admitted to going to extreme lengths to “save the world” and get the vaccines out faster during the COVID-19 pandemic.

Fortune

7 Prescription Price Increases Linked to Supplier Changes

We often assume drug prices rise solely due to corporate greed or inflation. In 2026, a different force is driving costs up. Structural changes in...

Saving Advice

Pfizer’s CEO on leading after a moonshot—and making deals with Trump

Also: All the news and watercooler chat from Fortune.

Fortune

What Are Wall Street Analysts' Target Price for Pfizer Stock?

Pfizer has lagged the broader market over the past year, and analysts remain cautious about its future outlook.

Barchart

Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All

As weight loss drugs move from injections to pills, this thematic ETF provides broad exposure for investors looking to profit from the industry’s next leg up.

MarketBeat

Today in ‘great’ America: Donald Trump decides to prove he can’t negotiate to save his life

What an awful deal.

We Got This Covered

This ETF Is Proof That the Healthcare Rebound Is Real

Track healthcare’s 2026 setup: GLP-1 drug adoption, a valuation gap vs. tech, and why VHT offers broad exposure with low fees and dividends.

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Unusual Options Activity in Pfizer: 2 Strategies Traders Are Jumping On

There were 1,399 unusually active options in Thursday’s trading. Pfizer’s March 20 $29 put had the highest Vol/OI ratio at 210.16. In the money by 12.8%, it sets up for a couple of different trading strategies.

Medical Daily

COVID Nimbus Explained: Key Symptoms, Warning Signs, and What You Need to Know

Get essential facts on COVID Nimbus (NB.1.8.1) symptoms, transmission, risk groups, prevention, and treatment to stay informed and protect your health.

MarketBeat

These 3 Stocks Trade at Discounts the Market Won’t Ignore Forever

With the S&P 500 trading at 26 times forward earnings, valuations are a concern entering 2026. Consider these 3 discounted stocks to insulate your portfolio.

The Independent UK

Despite Trump pressure, Big Pharma is raising hundreds of drug prices

Costs of at least 350 branded medications, including vaccines against Covid-19, shingles and cancer treatment Ibrance, will reportedly be hiked

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake

With activist investors gone and revenue stabilizing, the undervalued pharmaceutical giant offers a compelling chance for value investors in the coming year.

Kiplinger

Stocks Chop as the Unemployment Rate Jumps: Stock Market Today

November job growth was stronger than expected, but sharp losses in October and a rising unemployment rate are worrying market participants.

MarketBeat

Pfizer Adds to Its Big Bet on Weight Loss Drugs

A month after acquiring obesity biotech Metsera, Pfizer's expanding in the weight loss drug market after signing a licensing agreement for a weight loss pill.

The Conversation

Is there much COVID around? Do I need the new booster shot LP.8.1?

COVID rarely rates a mention in the news these days, yet it hasn’t gone away.

The Independent UK

Trump’s FDA plans to put a ‘black box’ warning on COVID vaccines: report

Black boxes are the FDA’s most serious warning sign and are usually placed on opioid products

Axios

This RFK Jr.-founded group demands the FDA kill the COVID vaccine

An anti-vaccine organization founded by Robert F. Kennedy Jr. filed a petition to remove the shots from the market.

International Business Times

Eli Lilly, Pfizer Among 19 Drugs Approved for China's Commercial Health Insurance

China approves 19 innovative drugs for commercial health insurance, opening new market opportunities for global and local drugmakers.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Trump Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.